The good thing is that the company is hoping to prove narmafotinib's value with both gem/abraxane and FOLFIRINOX. Given its mechanism of action, there doesn't seem a reason that it couldn't be used with either chemo regime whether its first line, second line, third line.
The good thing is that the company is hoping to prove...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
-0.005(2.08%) |
Mkt cap ! $91.57M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 24.0¢ | 23.0¢ | $766.6K | 3.262M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 179879 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 402089 | 6 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| ATX (ASX) Chart |